Objectives: This study describes the clinical outcomes and therapeutic drug monitoring (TDM) following posaconazole suspension pre-emptive therapy in lung transplant (LTx) recipients.
Introduction
Fungal infections are estimated to occur in 15%-35% of lung transplant (LTx) recipients. 1 Given the high mortality rates 2,3 and economic burden 4 associated with invasive fungal disease (IFD), there has been a shift towards the use of antifungal prophylaxis. The use of voriconazole prophylaxis 5, 6 or pre-emptive therapy 7 is well documented in the LTx setting. However, voriconazole is associated with a number of adverse events. 8, 9 Posaconazole, another azole antifungal, has good in vitro activity against a number of fungi including Aspergillus and the mucormycetes. Whilst posaconazole suspension is increasingly prescribed in the LTx setting, little is known about its safety and efficacy in LTx recipients and evidence for its use has been extrapolated mainly from the haematology setting. [10] [11] [12] Despite the availability of a sustained-release tablet, posaconazole suspension remains an essential alternative in patients with swallowing difficulties or in circumstances when the tablet form is unavailable. Therefore, this study aims to describe the clinical outcomes and trough plasma concentration (C min ) of posaconazole suspension in LTx recipients.
Methods

Study design and participants
This retrospective observational study was conducted at The Alfred, Melbourne, Australia. The Alfred is a tertiary university teaching hospital and has performed over 1200 LTx since 1990. 13 Antifungals are generally prescribed pre-emptively following isolation of fungi from respiratory specimens or empirically based on the presence of clinical signs and symptoms. Study participants were identified from the LTx database and pharmacy dispensing records. Only LTx recipients (18 years old) receiving posaconazole suspension monotherapy pre-emptively, either as the first antifungal post-LTx or following voriconazole, between 1 January 2009 and 31 December 2015 were included in the study. 
Outcomes assessment
Every LTx recipient undergoes routine surveillance bronchoscopy to monitor for infection and graft rejection. 13 Patients were followed for up to 12 months following commencement of the first antifungal post-LTx with clinical outcomes evaluated at 6 and 12 months. Patient outcomes were not evaluated if posaconazole suspension was prematurely discontinued and replaced by other antifungals during the follow-up period. Fungal infection and colonization were defined using the 2010 International Society for Heart and Lung Transplantation (ISHLT) consensus statements on definitions of infections in cardiothoracic transplant recipients. 16 Clinical outcomes were defined as eradication of colonization, new colonization, recurrent colonization or persistent colonization. 7 The safety of posaconazole suspension was evaluated based on adverse events, documented in the medical records.
Therapeutic drug monitoring (TDM)
TDM was routinely performed in all patients during hospitalization and at every outpatient clinic visit. Posaconazole dose, C min , and monitoring frequency of all patients included in the study were collected and analysed. C min was quantified using an in-house assay (ultra-performance LC-tandem MS, Waters Acquity system), validated by the National Association of Testing Authorities Australia.
Statistical analysis
Data analysis was performed using Stata 14.0 software (Stata Corp, College Station, TX, USA). Patient characteristics and outcomes were analysed using descriptive statistics. The difference between independent numerical variables was assessed using the Wilcoxon Mann-Whitney test where appropriate. A P value of 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 57 LTx patients received posaconazole suspension duringthe study period. Four patients had incomplete medical records. Of the remaining 53 patients, 42 were prescribed posaconazole suspension pre-emptively. The majority (34/42, 81%) received posaconazole suspension for post-LTx fungal colonization, which occurred at a median (IQR) of 186 (28-401) days post-LTx (Table 1) .
Patient outcomes
Posaconazole suspension was prescribed to 16/42 patients as the first-line antifungal following LTx for a median (IQR) of 129 (74.5-178) days. Fourteen patients completed the prescribed therapy, whilst two discontinued posaconazole suspension and received other antifungals: one owing to sub-therapeutic C min and the other due to the need for parenteral administration following Jeong et al.
intubation. Clinical outcomes were assessed in 14/16 patients. At 6 months, fungal colonization was eradicated in 13/14 patients (93%), whilst one patient (7%) had persistent Aspergillus colonization. This patient only received posaconazole suspension preemptively against pre-LTx Aspergillus colonization for 24 days. At 12 months, 12/13 patients (92%), who had eradication of colonization at 6 months, remained free of fungal colonization, whilst the other had recurrent Aspergillus fumigatus colonization. Neither death nor cases of IFD were observed in this patient cohort. The remaining 26/42 patients received posaconazole suspension for a median (IQR) of 118.5 (54-177) days as a substitute for voriconazole. The switchover occurred after a median (IQR) of 33 (13-73) days of voriconazole therapy, primarily following intolerance (20/26, 77%) . Of the 26 patients, premature discontinuation of posaconazole suspension, leading to administration of another antifungal, was observed in three patients: one due to concern about abnormal liver function, one experiencing nausea/ vomiting and one with persistently low posaconazole C min . At 6 months, of the 23 patients, who had their clinical outcomes assessed, only 14 (61%) had eradication of colonization; whereas two (9%) had persistent colonization (A. fumigatus) and three (13%) had new colonization (Aspergillus spp., Paecilomyces spp. and Scopulariopsis spp.). Additionally, one death not attributed to IFD and three cases of IFD (Scedosporium apiospermum osteomyelitis, Rhizopus spp. wound infection and aspergilloma) were documented. At 12 months, no fungi were isolated in 11 of 14 patients (79%) in whom fungal colonization was successfully eradicated at 6 months. Of the remaining three patients, one had recurrent A. fumigatus colonization, one had new colonization (Fusarium spp.) and one died due to bronchiolitis obliterans syndrome; Aspergillus terreus was recovered from the deceased's bronchial tissue. Additionally, three non-IFD related deaths (graft failure) were reported in this patient group.
TDM
Posaconazole C min was measured in 37/42 patients (88%); a total of 272 levels were recorded, giving a median (IQR) of 7 (3-11) levels per patient with the first level measured a median (IQR) of 7 (5-14) days post-initiation of posaconazole suspension. The initial median (IQR) C min following 400 mg twice-daily posaconazole suspension was 0.78 (0.46-1.19) mg/L. The C min amongst patients receiving a total posaconazole daily dose of 600 and 800 mg was not statistically different (P " 0.13). Doses beyond 800 mg daily did not appear to result in higher median C min (P " 0.17) (Figure 1 ).
Discussion
The outcomes following posaconazole suspension pre-emptive therapy in our study appeared to be favourable, particularly when prescribed de novo following LTx, given the absence of breakthrough IFD throughout the follow-up period and a high eradication of fungal colonization rate (93%) at 6 months. When prescribed following voriconazole, a lower fungal eradication rate (61%) was observed.
Neoh et al. 7 previously reported the fungal colonization eradication rate and incidence of IFD at 6 months associated with voriconazole pre-emptive therapy in LTx recipients to be 76% and 1.6%, respectively. The more favourable outcomes observed in our study, particularly in patients receiving posaconazole suspension as the first antifungal following LTx, may be associated with longer median duration of antifungal exposure in the posaconazole arm (129 days) compared to that in the previously reported voriconazole cohort (85 days 7 ) . Similarly, at 12 months, a higher proportion of patients receiving posaconazole suspension remained free of fungal colonization following fungal eradication at 6 months (90% in those receiving posaconazole as their first antifungal postLTx and 79% in those switching from voriconazole versus 70% of . Colonizations by Fusarium spp., Paecilomyces spp. and Scopulariopsis spp. were observed within a year post-LTx in the present study. Whilst infections associated with these fungi following broad-spectrum azole prophylaxis have previously been reported, they generally occurred years after transplantation. 17 It remains unknown whether the use of posaconazole could have led to the shift in the epidemiology and early emergence of these fungal organisms in the LTx population. Further surveillance is required.
In the present study, doses higher than 800 mg/day were prescribed, primarily to patients with cystic fibrosis, although this did not result in higher median C min , potentially due to reduced absorption. 18 Whilst the use of posaconazole injection 19 or tablet 20 has been shown to afford posaconazole C min .1 mg/L, this is yet to be demonstrated in either cystic fibrosis patients or LTx recipients. Further study should investigate posaconazole C min following administration of the newer posaconazole formulation in this patient cohort.
The present study suggests that early posaconazole suspension pre-emptive therapy in LTx recipients appears well tolerated and may potentially afford favourable clinical outcomes. However, larger multicentre studies are required to confirm these findings. Additionally, given the better exposure associated with posaconazole tablet and/or injection, clinical outcomes following administration of these formulations may be different to those observed in the current study. Importantly, the clinical outcomes and TDM of the newer posaconazole formulations need to be determined to assist the development of improved antifungal prescribing guidelines in the LTx setting.
